Literature DB >> 10399674

Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice.

J Tchekalarova1, V Georgiev.   

Abstract

The effects of adenosinergic and angiotensin IIergic agents and of their combinations on the seizure threshold in mice were determined by measuring the dose of timed-intravenous (tail vein) infused pentylenetetrazol (PTZ) required to elicit clonic seizures. All drugs were administered intracerebroventricularly (i.c.v.). Angiotensin II (ANG II), its peptide analogue sarmesin, the selective adenosine A1 receptor agonists N6-cyclopentyladenosine (CPA) and 2-chloroadenosine (2-ClAdo) significantly increased the PTZ seizure threshold. The selective AT1 receptor antagonist losartan blocked the anticonvulsant effect of ANG II, sarmesin and CPA. The selective AT2 receptor antagonist PD 123319 failed to block the effect of ANG II and sarmesin on the PTZ seizure threshold but reversed the threshold-increasing effect of CPA. The selective adenosine A1 receptor antagonist 8-(p-sulfophenyl)-theophylline (8-p-SPT) alleviated the threshold-increasing effect of CPA and ANG II. Concurrent injection of 2-ClAdo and ANG II as well as of 2-ClAdo and sarmesin, at doses which had no significant effect on the PTZ seizure threshold when given alone, acted synergistically, producing greater effect on the threshold. Taken together, the findings support the possibility of specific ANG II-adenosine A1 receptor interactions in the regulation of the PTZ seizure threshold.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399674     DOI: 10.1016/s0928-4257(99)80151-x

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  5 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

2.  Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy.

Authors:  Jana D Tchekalarova; Natasha Ivanova; Dimitrina Atanasova; Daniela M Pechlivanova; Nikolai Lazarov; Lidia Kortenska; Rumiana Mitreva; Valentin Lozanov; Alexander Stoynev
Journal:  Cell Mol Neurobiol       Date:  2015-10-13       Impact factor: 5.046

Review 3.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

4.  Investigation of the structure-activity relationship in a series of new LVV- and VV-hemorphin-7 analogues designed as potential anticonvulsant agents.

Authors:  Petar Todorov; Stela Georgieva; Petia Peneva; Jana Tchekalarova
Journal:  Amino Acids       Date:  2022-01-03       Impact factor: 3.520

Review 5.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.